The earnings call presented strong financial and operational performance with notable growth in procedure volumes and successful product launches. However, macroeconomic challenges in international markets and tariff impacts were highlighted as concerns.

Company Guidance

During the Intuitive Second Quarter 2025 earnings call, several key metrics and updates were highlighted. The company reported a 21% revenue growth, driven by a 17% increase in da Vinci procedures and strong capital placements, including 395 da Vinci systems. Of these, 180 were the newer da Vinci 5 systems, which have seen positive feedback and adoption. The installed base of da Vinci systems grew by 14% to almost 10,500 globally, with average system utilization rising by 2%. Specific regional growth included a 23% increase in procedures outside the U.S., with notable strength in India and Korea. The company's Ion systems also saw significant growth, with a 52% increase in procedures. Despite macroeconomic challenges in some international markets, Intuitive maintained strong financial performance, with a pro forma operating margin of 39% and a 23% increase in pro forma earnings per share. Looking forward, the company updated its 2025 procedure growth guidance to a range of 15.5% to 17% and expects a pro forma gross margin between 66% and 67% of revenue.

Record Revenue Growth

Revenue growth was reported at 21% year-over-year, reflecting strong procedure performance and capital placements.

Da Vinci Procedure Growth

Da Vinci procedure growth in the quarter was 17%, with benign general surgery leading U.S. procedure growth. International growth was driven by non-urology procedures.

Successful Launch of Da Vinci 5

The newest platform, Da Vinci 5, is in broad launch in the U.S. and received clearances in Europe and Japan. Customer feedback and adoption are positive.

Strong Performance in Emerging Markets

Regional performance highlights included strength in India, Korea, and distribution markets.

SP and Ion Systems Growth

SP procedure growth was strong at 88% year-over-year, and Ion procedures grew 52% to approximately 35,000 in the quarter.

Advanced Energy Instruments Progress

Received 510(k) clearance for vessel sealer curved, enhancing precision in narrow anatomical spaces.

Intuitive Surgical (ISRG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ISRG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 16, 2025	2025 (Q3)	1.99 / -	1.84	―	―	―
Jul 22, 2025	2025 (Q2)	1.93 / 2.19	1.78	23.03% (+0.41)
Apr 22, 2025	2025 (Q1)	1.74 / 1.81	1.5	20.67% (+0.31)
Jan 23, 2025	2024 (Q4)	1.79 / 2.21	1.6	38.12% (+0.61)	―
Oct 17, 2024	2024 (Q3)	1.64 / 1.84	1.46	26.03% (+0.38)
Jul 18, 2024	2024 (Q2)	1.54 / 1.78	1.42	25.35% (+0.36)
Apr 18, 2024	2024 (Q1)	1.42 / 1.50	1.23	21.95% (+0.27)	―
Jan 23, 2024	2023 (Q4)	1.48 / 1.60	1.23	30.08% (+0.37)	―
Oct 19, 2023	2023 (Q3)	1.42 / 1.46	1.19	22.69% (+0.27)	―
Jul 20, 2023	2023 (Q2)	1.33 / 1.42	1.14	24.56% (+0.28)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ISRG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 22, 2025	$511.00	$501.95	-1.77%
Apr 22, 2025	$478.74	$487.93	+1.92%
Jan 23, 2025	$608.66	$584.05	-4.04%
Oct 17, 2024	$473.73	$521.15	+10.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.